DR. MATTHEW ARTHUR MOVSESIAN, MD
Osteopathic Medicine at Foothill Blvd, Salt Lake City, UT

License number
Utah 175710-1205
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
500 Foothill Blvd, Salt Lake City, UT 84148
Phone
(801) 582-1565
(801) 328-4446
National Provider ID: 1700966876
LicenseFiles verified this license of Nov 7, 2017 at the National Plan and Provider Enumeration System.

Personal information

See more information about MATTHEW ARTHUR MOVSESIAN at radaris.com
Name
Address
Phone
Matthew Movsesian
S Salt Lake, UT
(801) 328-4446
Matthew A Movsesian, age 70
151 4Th Ave, Salt Lake City, UT 84103
(801) 328-4446
Matthew A Movsesian, age 70
151 4Th Ave, Salt Lake Cty, UT 84103
(801) 328-4446

Professional information

See more information about MATTHEW ARTHUR MOVSESIAN at trustoria.com
Matthew Movsesian Photo 1
Professor, Internal Medicine (Cardiology) And Pharmacology At University Of Utah School Of Medicine

Professor, Internal Medicine (Cardiology) And Pharmacology At University Of Utah School Of Medicine
Position:
Founder at Fourth West Bioscience, Professor, Internal Medicine (Cardiology) and Pharmacology at University of Utah School of Medicine
Location:
Salt Lake City, Utah
Industry:
Research
Work:
Fourth West Bioscience - Greater Salt Lake City Area since 2009 - Founder University of Utah School of Medicine - Greater Salt Lake City Area since 1986 - Professor, Internal Medicine (Cardiology) and Pharmacology VA Salt Lake City Health Care System - Greater Salt Lake City Area Jan 2002 - Aug 2009 - Chief, Cardiology Section UCSF Medical Center - San Francisco Bay Area 1984 - 1986 - Fellow, cardiovascular diseases National Institutes of Health - Bethesda, MD 1981 - 1984 - Postdoctoral fellow, molecular biology Northwestern University, Feinberg School of Medicine - Chicago, IL 1978 - 1981 - Resident, internal medicine
Education:
Harvard Medical School 1974 - 1978
Doctor of Medicine (MD) Columbia University in the City of New York 1971 - 1974
AB, Chemistry
Languages:
French, German

Matthew Movsesian Photo 2
Isoform-Selective Inhibitors And Activators Of Pde3 Cyclic Nucleotide Phosphodiesterases

Isoform-Selective Inhibitors And Activators Of Pde3 Cyclic Nucleotide Phosphodiesterases

US Patent:
2003015, Aug 21, 2003
Filed:
Jun 19, 2002
Appl. No.:
10/175161
Inventors:
Matthew Movsesian - Salt Lake City UT, US
International Classification:
A61K048/00, C12Q001/68, C07H021/04, C12N009/16, C12P021/02, C12N005/06
US Classification:
514/044000, 435/006000, 435/069100, 435/196000, 435/320100, 435/325000, 536/023200
Abstract:
The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.

Matthew Movsesian Photo 3
Isoform-Selective Inhibitor And Activators Of Pde3 Cyclic Nucleotide Phosphodiesterases

Isoform-Selective Inhibitor And Activators Of Pde3 Cyclic Nucleotide Phosphodiesterases

US Patent:
2010026, Oct 21, 2010
Filed:
Jan 18, 2007
Appl. No.:
11/654858
Inventors:
Matthew A. Movsesian - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.

Matthew Movsesian Photo 4
Pde1 As A Target Therapeutic In Heart Disease

Pde1 As A Target Therapeutic In Heart Disease

US Patent:
2012007, Mar 22, 2012
Filed:
Dec 2, 2009
Appl. No.:
13/132547
Inventors:
Matthew Movsesian - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61K 39/395, A61K 31/7088, A61K 38/02, A61P 9/00, A61P 9/04, C07K 16/40, C12Q 1/44, C40B 30/08, C07K 14/00, C07H 21/00, C07H 21/02, A61K 31/713, A61P 9/06
US Classification:
4241581, 514 44 A, 514 44 R, 514 164, 435 19, 506 11, 530350, 536 231, 536 245, 5303898
Abstract:
Disclosed are compositions and methods related to inhibition of PDE1.

Osteopathic Medicine licenses in Utah










Other Doctors licenses in Utah